WO2004022593A8 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Google Patents
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid moleculesInfo
- Publication number
- WO2004022593A8 WO2004022593A8 PCT/IB2003/004347 IB0304347W WO2004022593A8 WO 2004022593 A8 WO2004022593 A8 WO 2004022593A8 IB 0304347 W IB0304347 W IB 0304347W WO 2004022593 A8 WO2004022593 A8 WO 2004022593A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytokines
- nucleic acid
- acid molecules
- encoding nucleic
- higher stability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60332358T DE60332358D1 (en) | 2002-09-09 | 2003-09-08 | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE |
EP03794017A EP1539960B1 (en) | 2002-09-09 | 2003-09-08 | Protease-resistant modified interferon alpha polypeptides |
AT03794017T ATE466085T1 (en) | 2002-09-09 | 2003-09-08 | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES |
AU2003263552A AU2003263552A1 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
CA002498319A CA2498319A1 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40989802P | 2002-09-09 | 2002-09-09 | |
US60/409,898 | 2002-09-09 | ||
US45713503P | 2003-03-21 | 2003-03-21 | |
US60/457,135 | 2003-03-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004022593A2 WO2004022593A2 (en) | 2004-03-18 |
WO2004022593A3 WO2004022593A3 (en) | 2004-07-15 |
WO2004022593A8 true WO2004022593A8 (en) | 2007-05-18 |
Family
ID=31981642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/004347 WO2004022593A2 (en) | 2002-09-09 | 2003-09-08 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
Country Status (8)
Country | Link |
---|---|
US (12) | US7611700B2 (en) |
EP (1) | EP1539960B1 (en) |
AT (1) | ATE466085T1 (en) |
AU (1) | AU2003263552A1 (en) |
CA (1) | CA2498319A1 (en) |
DE (1) | DE60332358D1 (en) |
ES (1) | ES2343518T3 (en) |
WO (1) | WO2004022593A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP7050007B2 (en) | 2016-06-08 | 2022-04-07 | ヤンセン バイオテツク,インコーポレーテツド | GM-CSF mutant and usage |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2808804B1 (en) * | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
CA2491567A1 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
CA2500626A1 (en) * | 2002-10-01 | 2004-04-15 | Xencor, Inc. | Interferon variants with improved properties |
US20050054053A1 (en) * | 2002-10-01 | 2005-03-10 | Xencor, Inc. | Interferon variants with improved properties |
EP1608947A4 (en) * | 2002-10-02 | 2009-06-17 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
US7456257B2 (en) * | 2003-02-18 | 2008-11-25 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
WO2006076014A2 (en) * | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
MX2007001589A (en) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same. |
US20060073563A1 (en) * | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
US7211973B1 (en) * | 2005-01-07 | 2007-05-01 | Marvell Asia Pte, Ltd. | System and process for utilizing back electromotive force in disk drives |
CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
WO2006111745A2 (en) * | 2005-04-20 | 2006-10-26 | Viragen Incorporated | Composition and method for treating viral infection |
EP1877434A2 (en) * | 2005-05-04 | 2008-01-16 | Nautilus Biotech | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
TW200722104A (en) * | 2005-06-20 | 2007-06-16 | Pepgen Corp | Low-toxicity, long-circulating human interferon-α analogs |
US7767799B2 (en) * | 2005-06-29 | 2010-08-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Nucleic acid molecules encoding recombinant interferon-α2 (IFNα2) mutants |
WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
US20080096819A1 (en) | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
WO2007130453A2 (en) | 2006-05-02 | 2007-11-15 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
EP2423306A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
AR078117A1 (en) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE |
FR2905375A1 (en) * | 2006-08-29 | 2008-03-07 | Biomethodes Sa | Thermostable variants of human interferon alpha useful for preparing antiviral, antiproliferative or immunomodulatory medicaments have one or more selected amino acid substitutions |
ES2606034T3 (en) | 2006-09-28 | 2017-03-17 | Merck Sharp & Dohme Corp. | Pegylated IL-10 for use in the treatment of lymphoma |
CN101553499B (en) | 2006-10-10 | 2013-10-16 | 澳大利亚国立大学 | Process for generation of protein and uses thereof |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
ATE548381T1 (en) | 2008-05-29 | 2012-03-15 | Hanall Biopharma Co Ltd | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
MX2011000847A (en) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy. |
AU2009333325B2 (en) | 2008-12-17 | 2014-07-10 | Merck Sharp & Dohme Corp. | Mono- and di-peg IL-10 production; and uses |
US20110294733A1 (en) * | 2009-01-20 | 2011-12-01 | Hanall Biopharma Co., Ltd. | Modified human thrombopoietin polypeptide fragment and manufacturing method thereof |
TWI504405B (en) | 2009-01-22 | 2015-10-21 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
AU2010249047A1 (en) * | 2009-05-13 | 2011-11-24 | Protein Delivery Solutions, Llc | Pharmaceutical system for trans-membrane delivery |
US20100310509A1 (en) * | 2009-06-04 | 2010-12-09 | Ash John D | COMPOSITIONS COMPRISING MODULATORS OF SIGNAL TRANSDUCING RECEPTOR gp130 AND METHODS OF PRODUCING AND USING SAME |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
WO2011089255A1 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
EP2525833A2 (en) | 2010-01-22 | 2012-11-28 | Novo Nordisk Health Care AG | Stable growth hormone compounds |
EP2595661A1 (en) | 2010-07-22 | 2013-05-29 | Novo Nordisk Health Care AG | Growth hormone conjugates |
CN103547288B (en) | 2011-01-10 | 2016-03-16 | 密执安大学评议会 | Stem cell factor inhibitor |
US9732132B2 (en) * | 2011-01-14 | 2017-08-15 | Vanderbilt University | Therapeutic compositions and methods for disorders associated with neuronal degeneration |
CN103764665A (en) | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | Using sortases to install click chemistry handles for protein ligation |
NZ756727A (en) * | 2011-10-28 | 2022-12-23 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
EP2982686B1 (en) * | 2013-03-29 | 2018-06-27 | Glytech, Inc. | Polypeptide having sialylated sugar chains attached thereto |
ES2841123T3 (en) | 2013-04-05 | 2021-07-07 | Formulacion Del Compuesto De La Hormona De Crecimiento | Growth hormone compound formulation |
CA2908198A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CA2908208A1 (en) * | 2013-04-24 | 2014-10-30 | Armo Biosciences, Inc. | Interleukin-10 compositions and uses thereof |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
WO2015006554A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
EP3038642A4 (en) | 2013-08-30 | 2017-01-18 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
WO2015070751A1 (en) * | 2013-11-13 | 2015-05-21 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
CN106573072A (en) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | Methods of lowering serum cholesterol |
MX2017004838A (en) | 2014-10-14 | 2017-10-16 | Armo Biosciences Inc | Interleukin-15 compositions and uses thereof. |
ES2941234T3 (en) | 2014-10-22 | 2023-05-19 | Armo Biosciences Inc | Methods of using interleukin-10 for the treatment of diseases and disorders |
SG11201703251TA (en) | 2014-10-29 | 2017-05-30 | Teva Pharmaceuticals Australia Pty Ltd | INTERFERON α2B VARIANTS |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CA2985524C (en) * | 2015-05-12 | 2023-10-17 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
KR20180020141A (en) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | PEGylated interleukin-10 for cancer treatment |
CN108025040A (en) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | The method that disease and illness are treated using interleukin-10 |
SG11201808552XA (en) | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
US20190352363A1 (en) | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
EP3596118A4 (en) | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | Methods for modulating an immune response |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Targeted immunotolerance |
US10926283B2 (en) | 2017-04-12 | 2021-02-23 | Carolyn S. Jordan | Fingertip mist |
JP2020521452A (en) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | Targeted tolerance |
WO2019073315A1 (en) | 2017-10-09 | 2019-04-18 | Mansour Poorebrahim | Interferon-beta analog peptide |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
US20210292386A1 (en) * | 2018-07-24 | 2021-09-23 | Biontech Rna Pharmaceuticals Gmbh | IL2 Agonists |
JP2022504802A (en) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | 5T4 single domain antibody and therapeutic composition thereof |
JP2022512684A (en) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | B7H3 single domain antibody and therapeutic composition thereof |
CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
CA3169564A1 (en) * | 2020-03-31 | 2021-10-07 | Hanmi Pharm. Co., Ltd. | Novel immunostimulating il-2 analogs |
TW202208395A (en) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Family Cites Families (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US129584A (en) * | 1872-07-16 | Improvement in springs for gates and doors | ||
US134351A (en) * | 1872-12-31 | Improvement in crutches | ||
US175694A (en) * | 1876-04-04 | Improvement in sponge-cups | ||
US129203A (en) * | 1872-07-16 | Improvement in animal-traps | ||
US3171820A (en) * | 1964-02-17 | 1965-03-02 | Scott Paper Co | Reticulated polyurethane foams and process for their production |
US3224404A (en) * | 1964-11-06 | 1965-12-21 | Jong George E De | Mooring device |
GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) * | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US4302386A (en) * | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4363877B1 (en) * | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
US5221619A (en) * | 1977-11-08 | 1993-06-22 | Genentech, Inc. | Method and means for microbial polypeptide expression |
US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
US4898830A (en) * | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
US5510472A (en) * | 1979-11-21 | 1996-04-23 | Yeda Research And Development Co. Ltd. | Production of recombinant human interferon-beta2 |
US4816396A (en) * | 1980-03-10 | 1989-03-28 | Cetus Corporation | Method and vector organism for controlled accumulation of heterologous gene products in bacillus subtilis |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US4462985A (en) | 1980-08-22 | 1984-07-31 | University Of Illinois Foundation | Delivery of biologically active components of heterologous species interferon isolates |
US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
US4665160A (en) * | 1982-03-22 | 1987-05-12 | Genentech, Inc. | Novel human growth hormone like protein HGH-V encoded in the human genome |
DE3220116A1 (en) * | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
US4820515A (en) | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
US4497795A (en) | 1982-12-13 | 1985-02-05 | The Texas A&M University System | Method of regulating appetite and efficiency of food utilization employing interferon |
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4859600A (en) * | 1983-04-25 | 1989-08-22 | Genentech, Inc. | Recombinant procaryotic cell containing correctly processed human growth hormone |
US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
GB8317880D0 (en) | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
US5256546A (en) * | 1983-07-15 | 1993-10-26 | Bio-Technology General Corp. | Bacterial expression of porcine growth hormone |
BG49718A3 (en) * | 1983-07-15 | 1992-01-15 | Bio Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
US5198361A (en) * | 1983-07-15 | 1993-03-30 | Bio-Technology General Corp. | Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods |
US5637495A (en) * | 1983-07-15 | 1997-06-10 | Bio-Technology General Corp. | Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods |
US5670371A (en) * | 1983-07-15 | 1997-09-23 | Bio-Technology General Corp. | Bacterial expression of superoxide dismutase |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
KR850004274A (en) * | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US4937076A (en) | 1984-08-10 | 1990-06-26 | Combe Incorporated | Chewable aspirin and buffering material tablet and method for producing same |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
DE3588239T3 (en) * | 1985-03-30 | 2007-03-08 | Kauffman, Stuart A., Santa Fe | A method for obtaining DNA, RNA, peptides, polypeptides or proteins by DMS recombinant methods |
US5198345A (en) * | 1985-04-15 | 1993-03-30 | Gist-Brocades N.V. | Vectors in use in filamentous fungi |
US4845196A (en) * | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5631227A (en) * | 1985-09-18 | 1997-05-20 | The Upjohn Company | Somatotropin analogs |
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
US5298603A (en) * | 1985-12-21 | 1994-03-29 | Hoechst Aktiengesellschaft | GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use |
US4820514A (en) | 1985-12-30 | 1989-04-11 | Texas A&M University System | Low dosage of interferon to enhance vaccine efficiency |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP0240224A3 (en) * | 1986-03-31 | 1989-02-01 | Interferon Sciences, Inc. | An alpha interferon analogue |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
DK173067B1 (en) * | 1986-06-27 | 1999-12-13 | Univ Washington | Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines |
EP0260350B1 (en) | 1986-09-05 | 1992-02-12 | Cetus Oncology Corporation | Oxidation-resistant interferon-beta muteins and their production; formulations containing such muteins |
US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5017371A (en) * | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
US5698418A (en) * | 1988-02-17 | 1997-12-16 | Pharmacia & Upjohn Company | Fermentation media and methods for controlling norleucine in polypeptides |
US5068317A (en) * | 1988-03-15 | 1991-11-26 | Eli Lilly And Company | Novel derivative of human growth hormone |
US5445826A (en) * | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
CA1333777C (en) * | 1988-07-01 | 1995-01-03 | Randy M. Berka | Aspartic proteinase deficient filamentous fungi |
US5079345A (en) * | 1988-08-19 | 1992-01-07 | Eli Lilly And Company | Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism |
ES2154627T3 (en) * | 1988-08-24 | 2001-04-16 | American Cyanamid Co | STABILIZATION OF SOMATOTROPINS THROUGH THE MODIFICATION OF CISTEINE REMAINS USING DIRECTED LOCATION OR CHEMICAL DERIVATIZATION MUTAGENESIS. |
US5130422A (en) * | 1988-08-29 | 1992-07-14 | Monsanto Company | Variant somatotropin-encoding DNA |
US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5079230A (en) * | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
DE68929151T2 (en) * | 1988-10-28 | 2000-07-20 | Genentech Inc | METHOD FOR DETECTING ACTIVE DOMAINS AND AMINO ACID RESIDUES IN POLYPEPTIDES AND HORMONE VARIANTS |
US6780613B1 (en) * | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5101018A (en) * | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
US5663305A (en) * | 1989-07-10 | 1997-09-02 | The Upjohn Company | Somatotropin analogs |
DE3923963A1 (en) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE |
US5047511A (en) * | 1989-08-28 | 1991-09-10 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6583115B1 (en) * | 1989-10-12 | 2003-06-24 | Ohio University/Edison Biotechnology Institute | Methods for treating acromegaly and giantism with growth hormone antagonists |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5958879A (en) * | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
US6787336B1 (en) * | 1989-10-12 | 2004-09-07 | Ohio University/Edison Biotechnology Institute | DNA encoding growth hormone antagonists |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
JPH03151399A (en) | 1989-11-07 | 1991-06-27 | Snow Brand Milk Prod Co Ltd | Mutant human erythropoietin |
EP0510082A1 (en) * | 1990-01-08 | 1992-10-28 | Schering Corporation | Oxidized variants of gm-csf |
US4988798A (en) * | 1990-01-22 | 1991-01-29 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5109121A (en) * | 1990-01-22 | 1992-04-28 | Pitman-Moore, Inc. | Method for recovering recombinant proteins |
US5262568A (en) * | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
CA2079802C (en) * | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
US5951972A (en) * | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5399345A (en) * | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
HUT63185A (en) * | 1990-06-04 | 1993-07-28 | Schering Corp | Process for producing crystalline alpha-2-interferon |
US5849694A (en) * | 1990-07-16 | 1998-12-15 | Synenki; Richard M. | Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5871974A (en) * | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US6258530B1 (en) * | 1990-09-28 | 2001-07-10 | Ixsys, Inc. | Surface expression libraries of randomized peptides |
US5215741A (en) * | 1990-10-30 | 1993-06-01 | Amarillo Cell Culture Company, Incorporated | Method for prevention of parasite infections |
CA2044468C (en) * | 1990-11-21 | 2006-08-22 | Richard A. Nash | Canine granulocyte macrophage colony stimulating factor |
NZ240718A (en) * | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin analogues carrying mutations in the alpha-helix-1 region |
US5310882A (en) * | 1990-11-30 | 1994-05-10 | American Cyanamid Company | Somatotropins with alterations in the α-helix 3 region |
WO1992009690A2 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ES2087323T3 (en) * | 1991-02-19 | 1996-07-16 | Takeda Chemical Industries Ltd | METHOD FOR PRODUCING CYSTEINE-FREE PEPTIDES. |
ATE196548T1 (en) * | 1991-05-10 | 2000-10-15 | Genentech Inc | SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
JPH05289267A (en) * | 1992-04-07 | 1993-11-05 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US6436387B1 (en) * | 1992-11-24 | 2002-08-20 | G.D. Searle & Co. | Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5441734A (en) * | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
JPH08509614A (en) * | 1993-04-29 | 1996-10-15 | アボツト・ラボラトリーズ | Erythropoietin analog compositions and methods |
EP0626448A3 (en) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for preparing and purifying alpha-interferon |
JPH09501827A (en) * | 1993-06-11 | 1997-02-25 | ペストカ バイオメディカル ラボラトリーズ インコーポレイテッド | Superproteins including interferons and interleukins |
US6299870B1 (en) * | 1993-06-11 | 2001-10-09 | Pbl Biomedical Laboratories | Mutant human interferons |
SG52238A1 (en) * | 1993-07-28 | 1998-09-28 | Medvet Science Pty Ltd | Haemopoietic growth factor antagonists |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5798500A (en) * | 1993-08-10 | 1998-08-25 | Stillwagon, Jr.; Ross I. | Curling iron stove with internal cavity with electric heater positioned therebelow |
IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
US5939534A (en) * | 1993-12-29 | 1999-08-17 | Sumitomo Pharmaceuticals Company, Limited | Factors mutated in the D1 cap region |
US5597709A (en) * | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
WO1995023165A1 (en) * | 1994-02-23 | 1995-08-31 | Kyowa Hakko Kogyo Co., Ltd. | Platelet growth accelerator |
CA2183550A1 (en) | 1994-03-04 | 1995-09-08 | Craig M. Lewis | In vitro antibody affinity maturation using alanine scanning mutagenesis |
US5545723A (en) | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US6024734A (en) | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US6346243B1 (en) | 1994-04-12 | 2002-02-12 | Research Development Foundation | Inhibition of transplant rejection by type one interferon |
JP3560639B2 (en) | 1994-05-26 | 2004-09-02 | 株式会社タカハシキカン | Incinerator |
FR2722208B1 (en) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE |
US5460232A (en) * | 1994-07-25 | 1995-10-24 | Central Mine Equipment Company | Rotary earth drill bit socket shield |
US6099830A (en) * | 1994-08-09 | 2000-08-08 | Zymogenetics, Inc. | Methods for stimulating erythropoiesis using hematopoietic proteins |
IL116085A (en) * | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
US5814485A (en) | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
US5854049A (en) * | 1995-06-09 | 1998-12-29 | President And Fellows Of Harvard College | Plasmin-resistant streptokinase |
AUPN378095A0 (en) * | 1995-06-23 | 1995-07-20 | Bresagen Limited | Haemopoietic growth factor antagonists and uses therefor |
NZ286884A (en) * | 1995-06-29 | 1997-12-19 | Mitsui Chemicals Inc | Use of 20 kd human growth hormone in hrt, increasing serum igf-1 levels and stimulating lipolysis |
US6057103A (en) * | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
DE19535853C2 (en) * | 1995-09-18 | 1999-04-01 | Fraunhofer Ges Forschung | Variants of recombinant human interferon gamma, process for their preparation and their use |
EP1568771A3 (en) * | 1995-09-21 | 2006-05-17 | Genentech, Inc. | Human growth hormone variants |
PT858343E (en) | 1995-11-02 | 2004-07-30 | Schering Corp | THERAPY FOR CONTINUOUS INFUSE OF A LOW DOSE OF CYTOKINE |
US6171820B1 (en) * | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US6238884B1 (en) * | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US20030215798A1 (en) * | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
JP2000508521A (en) | 1996-01-23 | 2000-07-11 | バイロファーマ・インコーポレイテッド | Methods for identifying RNA virus inhibitors |
AU723494B2 (en) * | 1996-02-13 | 2000-08-31 | Jcr Pharmaceuticals Co., Ltd. | Mutant human growth hormones and their uses |
KR100394382B1 (en) | 1996-02-28 | 2004-02-05 | 유니하트 코포레이션 | Pharmaceutical composition consisting of natural human α-interferon |
US6096548A (en) * | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
IL126318A (en) * | 1996-03-29 | 2004-09-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents and some novel carrier compounds |
US6204022B1 (en) * | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
CN1151840C (en) | 1996-05-09 | 2004-06-02 | 太平洋制药控股公司 | Stimulation of host defence mechanisms against tumors |
US6207145B1 (en) | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
IL126971A0 (en) | 1996-05-09 | 1999-09-22 | Pharma Pacific Pty Ltd | Interferon compositions |
US5763239A (en) * | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
EP0874909A2 (en) * | 1996-08-23 | 1998-11-04 | Arch Development Corporation | Long-term expression of gene products by transforming muscle cells |
WO1998013487A1 (en) | 1996-09-27 | 1998-04-02 | Maxygen, Inc. | Methods for optimization of gene therapy by recursive sequence shuffling and selection |
US6967092B1 (en) * | 1996-10-25 | 2005-11-22 | Mc Kearn John P | Multi-functional chimeric hematopoietic receptor agonists |
DE19648625A1 (en) * | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Microprojectile for the introduction of substances into cells by ballistic transfer |
US5862514A (en) * | 1996-12-06 | 1999-01-19 | Ixsys, Inc. | Method and means for synthesis-based simulation of chemicals having biological functions |
BR9606270A (en) | 1996-12-18 | 1998-09-22 | Univ Minas Gerais | Process for the production of recombinant human beta-cis interferon protein and recombinant human beta-cis interferon protein |
US6884419B1 (en) * | 1996-12-23 | 2005-04-26 | Kyowa Hakko Kogyo, Co., Ltd. | hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same |
US5779434A (en) | 1997-02-06 | 1998-07-14 | Baker Hughes Incorporated | Pump mounted thrust bearing |
DE19717864C2 (en) * | 1997-04-23 | 2001-05-17 | Fraunhofer Ges Forschung | Human recombinant interferon beta, process for its preparation and its use |
US6153420A (en) * | 1997-04-24 | 2000-11-28 | Zymogenetics, Inc. | Serine protease polypeptides and materials and methods for making them |
WO1998050025A1 (en) * | 1997-05-08 | 1998-11-12 | Chugai Seiyaku Kabushiki Kaisha | Preventives/remedies for arteriosclerosis |
AU7383298A (en) * | 1997-05-13 | 1998-12-08 | Regents Of The University Of California, The | Novel antiangiogenic peptide agents and their therapeutic and diagnostic use |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
EP1881005B1 (en) * | 1997-07-14 | 2013-04-03 | Bolder Biotechnology, Inc. | Derivatives of G-CSF and related proteins |
US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
WO1999012969A1 (en) * | 1997-09-08 | 1999-03-18 | Metabolic Pharmaceuticals Ltd. | Treatment of obesity |
US6156509A (en) * | 1997-11-12 | 2000-12-05 | Genencor International, Inc. | Method of increasing efficiency of directed evolution of a gene using phagemid |
US6897297B1 (en) * | 1997-12-03 | 2005-05-24 | Curis, Inc. | Hydrophobically-modified protein compositions and methods |
US6165458A (en) * | 1997-12-26 | 2000-12-26 | Pharmaderm Laboratories Ltd. | Composition and method for dermal and transdermal administration of a cytokine |
US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
DE69825137T2 (en) * | 1998-02-23 | 2005-07-21 | Cilag Ag International | Liposomal erythropoietin dispersion |
US6036949A (en) * | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
US20040228834A1 (en) * | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US6174406B1 (en) * | 1998-04-09 | 2001-01-16 | International Business Machines Corporation | Bonding together surfaces |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
CA2330527A1 (en) * | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
US6472512B1 (en) | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
SK287491B6 (en) | 1998-10-16 | 2010-11-08 | Biogen Idec Ma Inc. | Interferon-beta-1 fusion proteins and their use |
PT1121156E (en) * | 1998-10-16 | 2006-05-31 | Biogen Idec Inc | CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES |
AUPP660698A0 (en) * | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
WO2000032387A1 (en) * | 1998-11-25 | 2000-06-08 | Amarillo Biosciences, Inc. | Interferon-alpha mediated upregulation of aquaporin expression |
EP1135493A2 (en) * | 1998-11-30 | 2001-09-26 | Eli Lilly And Company | Erythropoietic compounds |
US6171620B1 (en) * | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
US6555343B1 (en) * | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
US6946265B1 (en) * | 1999-05-12 | 2005-09-20 | Xencor, Inc. | Nucleic acids and proteins with growth hormone activity |
US6514729B1 (en) * | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
US6710025B1 (en) * | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
US6319691B1 (en) * | 1999-06-15 | 2001-11-20 | Usa Universe Bioengineering, Inc. | Fusion proteins comprising IFN-alpha2b and TM-alpha1 |
US6566329B1 (en) * | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
CZ299516B6 (en) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
KR100356140B1 (en) * | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | Modified Human Granulocyte-Colony Stimulating Factor and Process for Producing Same |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
EP1221976A4 (en) | 1999-09-28 | 2003-12-03 | Amarillo Biosciences Inc | Low dose ifn-gamma for treatment of disease |
EP1238082A2 (en) * | 1999-10-07 | 2002-09-11 | Maxygen, Inc. | Ifn-alpha homologues |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
WO2001032711A2 (en) | 1999-10-21 | 2001-05-10 | Board Of Trustees Of The University Of Arkansas | Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
CA2388982A1 (en) | 1999-11-05 | 2001-05-10 | Novozymes A/S | Microtiter plate (mtp) based high throughput screening (hts) assays |
BR0015506A (en) * | 1999-11-12 | 2002-07-23 | Maxygen Holdings Ltd | Gamma interferon conjugates, methods for their preparation, pharmaceutical compositions that comprise the molecules and their use in the treatment of diseases |
CA2393688A1 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
FR2802645B1 (en) | 1999-12-16 | 2002-03-08 | Meillat Roland | METHOD FOR EVALUATING THE PERFORMANCE OF A SET OF BIOLOGICAL AGENTS IN LIVE TARGET CELLS AND ITS APPLICATIONS |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
AU2001238397A1 (en) * | 2000-02-17 | 2001-08-27 | California Institute Of Technology | Computationally targeted evolutionary design |
AU780270B2 (en) * | 2000-02-23 | 2005-03-10 | Association Francaise Contre Les Myopathies | Treatment of immune diseases |
FR2808804B1 (en) | 2000-05-09 | 2002-08-02 | Nautilus Biotech | METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS |
AU5649901A (en) * | 2000-05-12 | 2001-11-20 | Univ Wales Medicine | Method for detecting growth hormone variations in humans, the variations and their uses |
ES2290142T3 (en) * | 2000-05-16 | 2008-02-16 | Bolder Biotechnology, Inc. | METHODS FOR REPLEGATION OF PROTEINS CONTAINING FREE CISTEINE RESIDUES. |
US7154958B2 (en) * | 2000-07-05 | 2006-12-26 | Texas Instruments Incorporated | Code division multiple access wireless system with time reversed space time block transmitter diversity |
CN101676400A (en) * | 2000-07-31 | 2010-03-24 | 比洛克西治疗公司 | Expression of biologically active polypeptides in duckweed |
EP1326825A2 (en) * | 2000-08-18 | 2003-07-16 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO2002015664A2 (en) | 2000-08-23 | 2002-02-28 | The New York Hospital Medical Center Of Queens | Methods of preventing or treating west nile virus and other infections |
FR2813314B1 (en) | 2000-08-25 | 2004-05-07 | Biomethodes | MASSIVE DIRECTED MUTAGENESIS PROCESS |
CA2421757A1 (en) * | 2000-09-08 | 2002-03-14 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
US20020169290A1 (en) | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
ATE399794T1 (en) * | 2001-02-06 | 2008-07-15 | Merck Patent Gmbh | MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENICITY |
BR0207015A (en) * | 2001-02-06 | 2004-07-06 | Merck Patent Ges Mit Beschroen | Modified erythropoientin (epo) with reduced immunogenicity |
PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
US7208147B2 (en) * | 2001-03-08 | 2007-04-24 | Merck Patent Gmbh | Modified granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity |
WO2002074783A2 (en) | 2001-03-15 | 2002-09-26 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
FR2823220B1 (en) * | 2001-04-04 | 2003-12-12 | Genodyssee | NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES |
US7271150B2 (en) * | 2001-05-14 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
US6833351B2 (en) * | 2001-05-21 | 2004-12-21 | Douglas T. Dieterich | Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
CA2459138A1 (en) * | 2001-09-04 | 2003-03-13 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified human growth hormone |
CA2403372A1 (en) * | 2001-09-13 | 2003-03-13 | Intier Automotive Inc. | Second row fold and pivot seat assembly |
US6930086B2 (en) * | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
EP1507540A4 (en) * | 2001-10-10 | 2006-12-06 | Centocor Inc | Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid |
EP2042196B1 (en) * | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
US6786634B2 (en) * | 2001-10-10 | 2004-09-07 | Noritake Co., Limited | Temperature measuring method and apparatus |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
AU2002360349A1 (en) * | 2001-11-09 | 2003-05-26 | Pharmacia And Upjohn Company | Single nucleotide polymorphisms in gh-1 |
GB0127213D0 (en) * | 2001-11-12 | 2002-01-02 | Univ Wales Medicine | Method of detecting growth hormone variations in humans the variations and their uses |
GB2384001B (en) * | 2001-12-14 | 2004-02-04 | Asterion Ltd | Chimeric growth hormone-growth hormone receptor proteins |
US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
CA2491567A1 (en) | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
US6809191B2 (en) * | 2002-07-03 | 2004-10-26 | Vaxim, Inc. | GM-CSF nucleic acid sequences |
BR0313135A (en) * | 2002-08-09 | 2005-07-05 | Merck Patent Gmbh | T cell epitopes in erythropoietin |
CN1684979A (en) * | 2002-08-31 | 2005-10-19 | 希杰株式会社 | Glycosylated human interferon alpha isoform |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
AU2003267700A1 (en) | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20050176627A1 (en) * | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
CA2500626A1 (en) | 2002-10-01 | 2004-04-15 | Xencor, Inc. | Interferon variants with improved properties |
US20050054053A1 (en) * | 2002-10-01 | 2005-03-10 | Xencor, Inc. | Interferon variants with improved properties |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
WO2004046365A2 (en) * | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
PA8588901A1 (en) * | 2002-11-20 | 2005-02-04 | Pharmacia Corp | CONJUGATES OF N-TERMINAL HUMAN GROWTH HORMONE HORMONE AND PROCESS FOR PREPARATION |
KR100541850B1 (en) | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | Mutein of human interferon-beta and its preparation method |
WO2005003157A2 (en) | 2003-06-10 | 2005-01-13 | Xencor, Inc. | Interferon variants with improved properties |
KR100632985B1 (en) * | 2003-07-26 | 2006-10-11 | 메덱스젠 주식회사 | A method of improving efficacy of biological response-modifying proteins and the example muteins |
WO2005070138A2 (en) * | 2004-01-08 | 2005-08-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
EP1718664A4 (en) * | 2004-02-02 | 2008-08-13 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
WO2005103076A2 (en) | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
WO2005110465A2 (en) | 2004-04-29 | 2005-11-24 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
MX2007001589A (en) | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same. |
US20060073563A1 (en) | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
MX2007002557A (en) | 2004-09-03 | 2007-10-10 | Creabilis Therapeutics Spa | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use. |
US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
GB0500099D0 (en) | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
EP1877434A2 (en) | 2005-05-04 | 2008-01-16 | Nautilus Biotech | Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides |
WO2007110230A2 (en) | 2006-03-27 | 2007-10-04 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
EP2423306A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
ATE548381T1 (en) | 2008-05-29 | 2012-03-15 | Hanall Biopharma Co Ltd | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
-
2003
- 2003-09-08 CA CA002498319A patent/CA2498319A1/en not_active Abandoned
- 2003-09-08 EP EP03794017A patent/EP1539960B1/en not_active Expired - Lifetime
- 2003-09-08 ES ES03794017T patent/ES2343518T3/en not_active Expired - Lifetime
- 2003-09-08 US US10/658,834 patent/US7611700B2/en active Active
- 2003-09-08 WO PCT/IB2003/004347 patent/WO2004022593A2/en not_active Application Discontinuation
- 2003-09-08 AT AT03794017T patent/ATE466085T1/en not_active IP Right Cessation
- 2003-09-08 AU AU2003263552A patent/AU2003263552A1/en not_active Abandoned
- 2003-09-08 DE DE60332358T patent/DE60332358D1/en not_active Expired - Lifetime
-
2005
- 2005-07-06 US US11/176,830 patent/US20060020116A1/en not_active Abandoned
-
2007
- 2007-01-22 US US11/656,921 patent/US20070254838A1/en not_active Abandoned
- 2007-02-06 US US11/703,610 patent/US20080075672A1/en not_active Abandoned
- 2007-02-07 US US11/704,141 patent/US20080194477A1/en not_active Abandoned
- 2007-02-13 US US11/706,088 patent/US7998469B2/en not_active Expired - Fee Related
- 2007-02-14 US US11/707,014 patent/US7650243B2/en not_active Expired - Fee Related
- 2007-07-05 US US11/825,604 patent/US20080159977A1/en not_active Abandoned
-
2008
- 2008-04-09 US US12/082,389 patent/US8057787B2/en not_active Expired - Fee Related
- 2008-04-09 US US12/082,365 patent/US8052964B2/en not_active Expired - Fee Related
- 2008-06-06 US US12/157,150 patent/US8114839B2/en not_active Expired - Fee Related
-
2011
- 2011-01-26 US US13/014,392 patent/US8105573B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8052964B2 (en) | 2002-09-09 | 2011-11-08 | Hanall Biopharma Co., Ltd. | Interferon-β mutants with increased anti-proliferative activity |
US8057787B2 (en) | 2002-09-09 | 2011-11-15 | Hanall Biopharma Co., Ltd. | Protease resistant modified interferon-beta polypeptides |
US8105573B2 (en) | 2002-09-09 | 2012-01-31 | Hanall Biopharma Co., Ltd. | Protease resistant modified IFN beta polypeptides and their use in treating diseases |
US8114839B2 (en) | 2002-09-09 | 2012-02-14 | Hanall Biopharma Co., Ltd. | Protease resistant modified erythropoietin polypeptides |
US7884073B2 (en) | 2004-11-04 | 2011-02-08 | Hanall Biopharma Co., Ltd. | Modified growth hormone |
US8252743B2 (en) | 2006-11-28 | 2012-08-28 | Hanall Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP7050007B2 (en) | 2016-06-08 | 2022-04-07 | ヤンセン バイオテツク,インコーポレーテツド | GM-CSF mutant and usage |
Also Published As
Publication number | Publication date |
---|---|
US20090053147A1 (en) | 2009-02-26 |
US7998469B2 (en) | 2011-08-16 |
US20080159977A1 (en) | 2008-07-03 |
ATE466085T1 (en) | 2010-05-15 |
CA2498319A1 (en) | 2004-03-18 |
US8057787B2 (en) | 2011-11-15 |
US8105573B2 (en) | 2012-01-31 |
US8052964B2 (en) | 2011-11-08 |
US20070224665A1 (en) | 2007-09-27 |
WO2004022593A2 (en) | 2004-03-18 |
US20080194477A1 (en) | 2008-08-14 |
AU2003263552A1 (en) | 2004-03-29 |
US20070254838A1 (en) | 2007-11-01 |
US20040132977A1 (en) | 2004-07-08 |
ES2343518T3 (en) | 2010-08-03 |
WO2004022593A3 (en) | 2004-07-15 |
US20080274081A9 (en) | 2008-11-06 |
US7650243B2 (en) | 2010-01-19 |
US20070172459A1 (en) | 2007-07-26 |
DE60332358D1 (en) | 2010-06-10 |
US20080075672A1 (en) | 2008-03-27 |
US20090123974A1 (en) | 2009-05-14 |
US20090131318A1 (en) | 2009-05-21 |
EP1539960B1 (en) | 2010-04-28 |
US8114839B2 (en) | 2012-02-14 |
US20110142801A1 (en) | 2011-06-16 |
AU2003263552A8 (en) | 2004-03-29 |
US20060020116A1 (en) | 2006-01-26 |
EP1539960A2 (en) | 2005-06-15 |
US7611700B2 (en) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004022593A8 (en) | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules | |
EP1624065A3 (en) | Agarase and gene thereof | |
AU2003252111A1 (en) | Fluorescent proteins, nucleic acids encoding them and methods for making and using them | |
WO2003066879A3 (en) | Amino acid transporters | |
AU2002258630A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
WO2002079384A9 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002257075A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
AU2002303137A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
WO2003016465A3 (en) | Cell cycle regulator protein | |
AU2003284579A1 (en) | PROTEIN FORMING COMPLEX WITH c-Fos PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD OF USING THE SAME | |
AU2002258618A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003215179A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof | |
AU2003222241A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003209105A1 (en) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof | |
AU2002258629A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002311750A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002314731A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002303180A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003220013A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003225666A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2003215212A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
AU2002240295A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003225626A1 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2003221757A1 (en) | Nucleic acid molecules encoding human proteins, and uses thereof | |
WO2005111069A3 (en) | Morphogenic proteins and stimulatory factors in gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2498319 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003794017 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003794017 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |